|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Issuer) |
Common Stock, par value $0.001 per share (Title of Class of Securities) |
(CUSIP Number) |
Richard Kaiser 2020 General Booth Blvd., Ste. 230, Virginia Beach, VA, 23454 7573066090 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
04/22/2026 (Date of Event Which Requires Filing of This Statement) |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Nexus Capital Investments, Inc. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
WYOMING
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
26,700,000.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
79.6 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, par value $0.001 per share |
| (b) | Name of Issuer:
BIOFORCE NANOSCIENCES HOLDINGS, INC. |
| (c) | Address of Issuer's Principal Executive Offices:
2020 GENERAL BOOTH BLVD, SUITE 230, VIRGINIA BEACH,
VIRGINIA
, 23454. |
| Item 2. | Identity and Background |
| (a) | Gretchen Privett, President and Secretary, Nexus Capital Investments, Inc., a Wyoming Corporation. |
| (b) | 125 Old Monroe Road, Athens, GA, 30606 |
| (c) | Nexus Capital Investments, Inc., President and Secretary, 125 Old Monroe Road, Athens, GA, 30606 |
| (d) | NONE |
| (e) | NONE |
| (f) | USA |
| Item 3. | Source and Amount of Funds or Other Consideration |
The Reporting entity acquired the 26,700,000 shares of common stock of BFNH in a private transaction for the purchase price of $400,000, and such funds were obtained through operational working capital. | |
| Item 4. | Purpose of Transaction |
(a) N/A
(b) BFNH and the Reporting Entity reserve the right to engage in the acquisition of other entities in the form of a merger or acquisition in the future;
(c) BFNH and the Reporting Entity reserve the right to engage in the sale or transfer of a material amount of assets in the future;
(d) No changes are forthcoming but the Conpany the reserves the right to change the management, the board and their terms in the future;
(e) BFNH reserves the right to change the capital structure of the Company in the future.
(f) N/A
(g)N/A
(h)N/A
(i) N/A
(jj) N/A
| |
| Item 5. | Interest in Securities of the Issuer |
| (a) | 26,700,000 is approximately 79.6% based on 33,549,005 shares of common stock outstanding as reported in BFNH's June 30, 2026 Form 10Q. |
| (b) | 26,700,000 |
| (c) | Except as otherwise disclosed herein, during the past 60 days the Reporting Persons has not effected trades in the shares of common stock of the Issuer. |
| (d) | No other persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares. |
| (e) | N/A |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
Except for the transactions described in this Schedule 13D, to the knowledge of the Reporting Persons, as of the date hereof, there are no contracts, arrangements, understanding or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons or any other persons with respect to any securities of the Issuer. | |
| Item 7. | Material to be Filed as Exhibits. |
None |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|